Key result
RSV causes significant morbidity and mortality in immunocompromised patients, requiring targeted prevention and vaccine trials.
Why the study?
Respiratory syncytial virus causes significant morbidity and mortality in immunocompromised patients, with disease severity varying by underlying immunologic pathologies and limited treatment options available.
This review highlights the significant impact of RSV in immunocompromised populations and discusses current and emerging prevention and treatment strategies.
RSV prevention strategies merit evaluation in immunocompromised patients; leaves open prospective efficacy and implementation data.
Respiratory syncytial virus (RSV) is a significant cause of morbidity and mortality in infants, older adults, and patients with weakened immune systems. Disease severity differs by underlying immunologic pathologies, with worse outcomes associated with progression from upper to lower respiratory disease. In this review we address the impact of RSV in immunocompromised populations, and discuss the limited available treatments and the potential impact of newer RSV prevention strategies on immunocompromised adults and children.
No takes yet. Share an insight, caveat, or question.
Koval et al. (2024) conducted a review in Respiratory syncytial virus (RSV) infection in immunocompromised patients. RSV prevention and treatment strategies was evaluated. Respiratory syncytial virus causes significant morbidity and mortality in immunocompromised patients, highlighting the need for targeted prevention strategies and clinical trials of newly approved vaccines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: